Updated 25/05/2026
UK scientists are racing to develop a vaccine for the Bundibugyo strain of Ebola virus that could enter clinical trials within months, according to the BBC. The Bundibugyo species kills approximately one-third of those infected and currently has no proven vaccine, leaving vulnerable populations exposed to potential outbreaks.
Ebola virus species by case fatality rates
Percentage of infected patients who die, by species
Source: World Health Organization, 2023 | Georgian Medical Journal News
Vaccine development accelerates amid public health concerns
Research teams across the UK are working urgently to develop an effective vaccine against the Bundibugyo strain, which was first identified in Uganda’s Bundibugyo district in 2007. Unlike the more common Zaire ebolavirus strain, which has an established vaccine, Bundibugyo remains without proven immunization options.
The World Health Organization has emphasized the critical need for vaccines against all Ebola species, particularly following lessons learned from the 2014-2016 West Africa outbreak that killed over 11,000 people.
Global health implications
The Bundibugyo strain poses particular challenges for global health security due to its moderate mortality rate. Uganda, where the strain was first identified, continues to experience periodic viral hemorrhagic fever outbreaks. The Centers for Disease Control and Prevention maintains surveillance programs across Central and East Africa to monitor Ebola emergence patterns.
Key takeaways
- Bundibugyo Ebola kills approximately 33% of infected patients but lacks an approved vaccine
- UK scientists aim to begin clinical trials within months
- The Bundibugyo strain was first identified in Uganda’s Bundibugyo district in 2007
- WHO emphasizes the need for vaccines against all Ebola species
Frequently asked questions
How deadly is the Bundibugyo Ebola strain?
According to the BBC report, Bundibugyo Ebola kills around a third of those infected, making it a serious public health threat that currently lacks a proven vaccine.
When could clinical trials begin?
According to the BBC, UK scientists are developing a vaccine that could be ready for trials in months.
Where was the Bundibugyo strain discovered?
The Bundibugyo strain was first identified in Uganda’s Bundibugyo district in 2007.
The development of a Bundibugyo Ebola vaccine represents a critical advancement in pandemic preparedness, addressing a significant gap in current immunization strategies. As UK scientists work toward clinical trials, the global health community watches closely for breakthrough results that could protect vulnerable populations.
Source: UK scientists developing Ebola vaccine that could be ready for trials in months
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
